Nexalin Technology, Inc. announced positive results from a clinical study published in the Journal of Affective Disorders, showing its Deep Intracranial Frequency Stimulation (DIFS) technology significantly reduced blood pressure in patients with major depressive disorder (MDD). The study highlighted that patients with higher baseline blood pressure experienced the most significant improvements, and the treatment was well-tolerated without reported adverse effects. The research demonstrates the potential of DIFS to address both mental and physical health challenges through a non-invasive approach.
This development holds significant implications for the treatment of MDD. The comorbidity of MDD and hypertension presents a complex challenge for clinicians. Current treatment options often focus solely on the mental health aspect, neglecting the interconnectedness of physical and mental well-being. Nexalin’s DIFS technology offers a potential solution by simultaneously addressing both conditions, potentially leading to improved patient outcomes and a more holistic approach to treatment. This could reduce the need for multiple medications and therapies, simplifying treatment regimens and potentially lessening the burden on patients.
The randomized controlled trial involved 68 first-episode, drug-naive MDD patients who received either active DIFS or sham stimulation over four weeks. Targeting brain regions associated with blood pressure regulation, such as the brainstem, hypothalamus, and thalamus, the active DIFS group experienced a reduction in systolic and diastolic blood pressure by 2.04 mmHg and 1.92 mmHg, respectively. These results were noticeable as early as week four.
The positive results from this study strengthen Nexalin’s position in the neurostimulation field. The findings support the potential of DIFS technology to expand beyond mental health applications and into broader areas of systemic wellness, such as cardiovascular health. This could open new markets for Nexalin and position the company as a leader in innovative, non-invasive treatment solutions for a range of health conditions. With ongoing trials for other conditions like Alzheimer’s disease and PTSD, coupled with expanding regulatory approvals, Nexalin is poised for future growth and broader clinical application of its DIFS technology.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.